Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Biognosys Group

## Sitemaps
[XML Sitemap](https://biognosysgroup.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Autumn Edition: Metabolic Signatures of Aging ](https://biognosysgroup.com/metabolic-signatures-of-aging/): As autumn approaches, seasonal change reminds us that our biology is continuously evolving throughout life. Aging is accompanied by measurable shifts in metabolism, many of which reflect the complex relationship between the human host and the gut microbiome. 

## Pages
- [News and Events](https://biognosysgroup.com/news-and-events/): Keep up with the latest from the Biognosys Group — from press releases and scientific collaborations to the conferences we attend and the events we host. Whether you're following our research milestones, looking to connect at an industry meeting, or joining one of our user meetings or webinars, this is your central hub for everything happening across Biognosys Group.
- [Spectronaut](https://biognosysgroup.com/spectronaut-2/): Powerful software package for comprehensive analysis of data-independent acquisition (DIA) proteomics experiments.
- [Careers](https://biognosysgroup.com/company/careers/): Lorem ipsum dolor sit amet, consetetur sadi pscing elitr, sed diam nonumy eirmod tempor.
- [Blog](https://biognosysgroup.com/blog/): Explore our blog and dive deeper into the science, insights, and stories behind our solutions.
- [Products](https://biognosysgroup.com/cro-services/proteomics/products/): Generate comprehensive, quantitative proteome maps to address complex biological questions. Our discovery workflows support unbiased analysis across a wide range of sample types and applications, combining label-free DIA with robust, optimized protein preparation for consistent and high-quality data. 
- [Posters](https://biognosysgroup.com/posters-test/): Don’t miss out on the latest from Biognosys Group – sign up to receive the latest news, innovations, and expert insights straight to your inbox.
- [Discover](https://biognosysgroup.com/discover/): Explore our library of resources and dive deeper into the science behind our solutions.
- [Cookie Notice](https://biognosysgroup.com/legal/cookie-notice/): We use cookies and other tracking technologies on our website. Some are essential to operate our website (Strictly Necessary Cookies). We also use cookies to analyze the traffic on our website and improve its performance (Performance Cookies), to provide you with enhanced functionality and personalization (Functional Cookies), and to build a profile of your interests and show you relevant ads (Targeting and Advertising Cookies). Learn more about how we handle your personal information in our Cookie Notice. 
- [About us](https://biognosysgroup.com/company/about-us/): The Biognosys Group unites PreOmics, Biognosys, biocrates, and PepSep under one organization. Originating from academic laboratories that helped shape key advances in mass spectrometry, the Group brings together complementary capabilities across proteomics, metabolomics, and lipidomics.
- [Terms and Conditions](https://biognosysgroup.com/legal/terms-and-conditions/): Last updated: 01 May 2026
- [Privacy Notice](https://biognosysgroup.com/legal/data-privacy/): Last updated: 1 May, 2026
- [Metabolomics & Lipidomics](https://biognosysgroup.com/products/metabolomics-lipidomics/)
- [Proteomics](https://biognosysgroup.com/products/proteomics/)
- [Metabolomics & Lipidomics](https://biognosysgroup.com/cro-services/ml/)
- [Proteomics](https://biognosysgroup.com/cro-services/proteomics/)
- [CRO – M&L – Pathway-Specific](https://biognosysgroup.com/cro-services/ml/pathway-specific/): Metabolites and lipids directly reflect biological function and disease state. As the molecular layer closest to phenotype, they capture host and microbial metabolic activity underlying health and disease. Our metabolomics and lipidomics services for pathway specific assays deliver the sensitivity and quantitative precision needed to address focused biological, translational, and clinical questions.
- [CRO – M&L – Targeted Profiling](https://biognosysgroup.com/cro-services/ml/targeted-profiling/): Metabolites and lipids directly reflect biological function and disease state. As the molecular layer closest to phenotype, they capture host and microbial metabolic activity underlying health and disease.
- [CRO – M&L – Data Analysis and Biostatistics](https://biognosysgroup.com/cro-services/ml/data-analysis-and-biostatistics/): Our metabolic phenotyping services deliver quality‑controlled, highly reproducible quantitative analysis across the metabolic spectrum. Beyond measurement, confident decision‑making requires robust statistical analysis and expert data interpretation. We therefore support every stage of your project, from study design and project management to statistical analysis and biomedical interpretation, helping you extract maximum value from your data.
- [CRO – Proteomics – NULISA](https://biognosysgroup.com/cro-services/proteomics/nulisa/): The NULISA technology by Alamar Corporation integrates a proprietary sequential immunocomplex capture and release workflow with Next-Generation Sequencing (NGS) or qPCR readout to achieve ultra-high sensitivity and scalable multiplexing. This approach enables the detection of low-abundance biomarkers in plasma or biofluid.
- [CRO – Proteomics – Immunopeptidomics](https://biognosysgroup.com/cro-services/proteomics/immunopeptidomics/): Immunopeptidomics is a mass spectrometry–based approach that identifies peptides presented by MHC (HLA) molecules on the cell surface. It is uniquely relevant because it reveals directly which antigens are displayed to T cells, rather than inferred from gene expression or in‑silico predictions. By directly linking the proteome to immune recognition, immunopeptidomics enables more reliable target discovery, validation, and prioritization in cancer immunotherapy, autoimmunity, and vaccine research.
- [CRO – Proteomics – Chemoproteomics](https://biognosysgroup.com/cro-services/proteomics/chemoproteomics/): Chemoproteomics bridges chemical biology and proteomics, delivering mechanistic, proteome-wide insights that accelerate hit-to-lead/lead optimization stages in small molecule drug discovery. Bionosys’ LiP-MS technology provides a unique label-free approach that can identify binding targets in complex proteomes.
- [CRO – Proteomics – Clinical and Targeted Proteomics](https://biognosysgroup.com/cro-services/proteomics/clinical-targeted-proteomics/): Protein quantification for biomarker analysis, pharmacodynamics, and target engagement studies is performed using Biognosys’ TrueSignature platform or SISCAPA immuno-enrichment to enable ultra-sensitive readouts and is available for both research use and fully GCP-compliant clinical applications.
- [CRO – Proteomics – Data Solutions](https://biognosysgroup.com/cro-services/proteomics/data-solutions/): Biognosys’ mass spectrometry-based Digital Proteome is one of the most comprehensive resources available for tissue specific protein expression, covering over 20 healthy and diseased tissue types from both human and preclinical species. Continuously expanded with new tissues and species, the dataset serves as a robust reference for biomarker discovery, translational research, and tissue-targeted drug development. 
- [CRO – Proteomics – Discovery Proteomics](https://biognosysgroup.com/cro-services/proteomics/discovery-proteomics/): Generate comprehensive, quantitative proteome maps to address complex biological questions. Our discovery workflows support unbiased analysis across a wide range of sample types and applications, combining label-free DIA with robust, optimized protein preparation for consistent and high-quality data. 
- [Overview – M&L CRO](https://biognosysgroup.com/ml-cro/): Our metabolic phenotyping services enable quality-controlled, highly reproducible, quantitative analysis across the metabolic spectrum. They cover a wide range of physiological processes and metabolic pathways that can be customized to best fit any metabolomics project. Choose from 12 targeted quantitative assays covering over 1,500 relevant metabolites, applicable to a wide range of sample types and species.
- [Overview – Proteomics CRO](https://biognosysgroup.com/proteomics-cro/): Biognosys delivers industry-leading proteomics contract research services from its laboratories in Boston and Zurich.
- [Overview – M&L Kits and Software](https://biognosysgroup.com/overview-ml-kits-and-software/): biocrates’ targeted metabolomics and lipidomics kits enable standardized, quality‑controlled, and highly reproducible quantitative analysis across a broad range of metabolic pathways. The portfolio includes comprehensive profiling kits, pathway‑specific solutions, and application‑focused assays, covering more than 1,200 metabolites across diverse species, biological matrices, and experimental settings. 
- [Overview – MS Life Science Consumables](https://biognosysgroup.com/ms-lifescience-consumables/): Advance your analytical workflows with Bruker’s high-performance MS-based solutions, designed to deliver exceptional sensitivity, reproducibility, and ease of use.  
- [Overview – Proteomics Software](https://biognosysgroup.com/proteomics-software/): Biognosys software provides an end‑to‑end proteomics ecosystem for a wide range of discovery and validation workflows. From high‑performance DIA and DDA analysis to targeted proteomics, cloud‑scale orchestration, and instrument monitoring, our solutions are built for speed, scalability, and reproducibility.
- [Contact](https://biognosysgroup.com/contact/): Thank you for your interest in Biognosys Group.
- [Overview – Proteomics Consumables](https://biognosysgroup.com/proteomics-consumables/): Proteomics consumables are designed to streamline and standardize LC–MS sample preparation workflows, enabling fast, robust, and reproducible proteomics across a wide range of biological samples.
- [Homepage](https://biognosysgroup.com/): A future where deep omics data reveals the full story of biology, unlocking discoveries that transform our understanding of health and disease. 
- [Products](https://biognosysgroup.com/products/)
- [Company](https://biognosysgroup.com/company/)
- [CRO Services](https://biognosysgroup.com/cro-services/)

## Distributors
- [Distributor](https://biognosysgroup.com/?distributor=distributor-5)
- [Distributor](https://biognosysgroup.com/?distributor=distributor-4)
- [Distributor](https://biognosysgroup.com/?distributor=distributor-3)
- [Distributor](https://biognosysgroup.com/?distributor=distributor-7)
- [Distributor](https://biognosysgroup.com/?distributor=distributor-6)
- [Distributor](https://biognosysgroup.com/?distributor=distributor-8)
- [Distributor](https://biognosysgroup.com/?distributor=distributor-9)
- [Distributor](https://biognosysgroup.com/?distributor=distributor-2)
- [Distributor](https://biognosysgroup.com/?distributor=distributor)

## Events
- [ItPA 2026](https://biognosysgroup.com/event/itpa-2026/)
- [HUPO-HIPP 2026](https://biognosysgroup.com/event/hupo-hipp-2026/)
- [Advancing Host Cell Protein Characterization With Proteomics](https://biognosysgroup.com/event/hcp-webinar-2026/)
- [Alzheimer’s Association International Conference](https://biognosysgroup.com/event/aaic-2026/)
- [Spectronaut User Group Meeting in Basel](https://biognosysgroup.com/event/spectronaut-user-group-meeting-basel-2026/)
- [HUPO World Congress](https://biognosysgroup.com/event/hupo-2026/)
- [46th BMSS Annual Meeting](https://biognosysgroup.com/event/bmss-2026/)
- [26th International Mass Spectrometry Conference](https://biognosysgroup.com/event/imsc-2026/)
- [Brixen Proteomics Summer School 2026](https://biognosysgroup.com/event/brixen-proteomics-summer-school-2026/)
- [74th ASMS Conference on Mass Spectrometry and Allied Topics](https://biognosysgroup.com/event/asms-2026/): on Mass Spectrometry and Allied Topics

## News
- [Biognosys Showcases Next-Gen Multiomics Innovations at ASMS 2026](https://biognosysgroup.com/news/2026-asms-next-gen-multiomics-innovations/): • Spectronaut 21 (DIA) and SpectroMine 6 (DDA): for increased identifications. Spectronaut 21 offers faster cloud-based processing with smaller SNE file sizes, enhanced PTM identification & site localization confidence, deep learning improvements for CCS prediction and deep learning models to enhance improvements of rare, unseen PTMs
- [Biognosys Group Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson’s Disease Research Through the Development of Improved Biomarker Assays](https://biognosysgroup.com/news/2026-collaboration-michael-j-fox-foundation/): April 14, 2026 – ZURICH, Switzerland. Biognosys Group, a leading provider of proteomics, metabolomics, and lipidomics solutions, today announced a major collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the development of highly sensitive and quantitative biomarker assays for Parkinson’s disease. The collaboration supports MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE), a global initiative designed to accelerate the development of therapies and biomarkers targeting leucine-rich repeat kinase 2 (LRRK2), the most common genetic risk factor for late-onset Parkinson’s disease.

## Products
- [Immunopeptidomics](https://biognosysgroup.com/product/immunopeptidomics/)
- [BeatBox](https://biognosysgroup.com/product/beatbox/)
- [Spectronaut](https://biognosysgroup.com/product/spectronaut/)
- [PepSep Columns](https://biognosysgroup.com/product/pepsep-columns/)
- [biocrates Quant 1000 Kit](https://biognosysgroup.com/product/biocrates-quant-1000-kit/)
- [P2-iST Plasma](https://biognosysgroup.com/product/p2-ist-plasma/)
- [iST](https://biognosysgroup.com/product/ist/)
- [OmicsFlow](https://biognosysgroup.com/product/omicsflow/)
- [iST-S Kit](https://biognosysgroup.com/product/ist-s-kit/)
- [Spectranaut 21 Software](https://biognosysgroup.com/product/spectranaut-21-software/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn-8/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn-7/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn-6/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn-5/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn-4/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn-3/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn-2/)
- [iST-REG-PSI 96HT (192rxn)](https://biognosysgroup.com/product/ist-reg-psi-96ht-192rxn/)

## Resources
- [Advancing Plasma Proteomics Through a Next-Generation Single- Particle Enrichment Workflow for Deeper and More Quantitative Biomarker Discovery](https://biognosysgroup.com/?resource=ismc-2026-advancing-plasma-proteomics-through-a-next-generation-single-particle-enrichment-workflow-for-deeper-and-more-quantitative-biomarker-discovery)
- [In-Depth Characterization of the P2 Enrichment Workflow Beyond EDTA Plasma](https://biognosysgroup.com/?resource=imsc-2026-in-depth-characterization-of-the-p2-enrichment-workfl-ow-beyond-edta-plasma)
- [Detection of In Source Fragmentation Enhances Library Free DIA for Immunopeptidomics](https://biognosysgroup.com/?resource=detection-of-in-source-fragmentation-enhances-library-free-dia-for-immunopeptidomics)
- [Proteomics in Real-World Applications: Plasma Biomarker Discovery and Oncology Drug Development](https://biognosysgroup.com/?resource=proteomics-in-real-world-applications-plasma-biomarker-discovery-and-oncology-drug-development)
- [ASMS 2026 | Spectronaut 21: Proteomics Without Blind Spot](https://biognosysgroup.com/?resource=spectronaut-21-proteomics-without-blind-spot)
- [Automation of P2 Nanoparticle-Based Plasma Enrichment on the Opentrons Enables Scalable, Reproducible Plasma Proteomics](https://biognosysgroup.com/?resource=asms-2026-automation-of-p2-nanoparticle-based-plasma-enrichment-on-the-opentrons-enables-scalable-reproducible-plasma-proteomics)
- [Identifying Circulating Biomarkers for Amyloid Conversion and Early Cognitive Decline Through Unbiased Proteomics in Matched CSF and Plasma](https://biognosysgroup.com/?resource=2026_asms_poster_wp077)
- [Generalizing Deep Learning Predictions to Unseen PTMs with Atomic Encoding](https://biognosysgroup.com/?resource=2026-asms-poster-wp047)
- [Boosting Sample Preparation at Low Protein Input: A Workflow Engineered for Optimal Recovery and High Throughput](https://biognosysgroup.com/?resource=2026_asms_poster_tp426)
- [Optimized FFPE Tissue Processing: Complete Workflow for In-Depth Proteome Analysis of Multiple FFPE Formats](https://biognosysgroup.com/?resource=2026_asms_poster_tp425)
- [Retention Time Down-Sampling Improves Sensitivity and Lower Limits of Quantification of prm-PASEF](https://biognosysgroup.com/?resource=2026_asms_poster_tp052)
- [Development and Qualification of an Ultra-Sensitive SISCAPA-MS Assay for UBE3A Quantification in Human CSF for Angelman Syndrome Research](https://biognosysgroup.com/?resource=2026_asms_poster_thp602)
- [Sensitive Antigen Discovery Using Library Free DIA with Integrated In-Source Fragmentation Detection](https://biognosysgroup.com/?resource=2026_asms_poster_thp461)
- [In-Depth Characterization of the P2 Enrichment Workflow](https://biognosysgroup.com/?resource=2026_asms_poster_thp080)
- [In-Depth Plasma Proteome Profiling Reveals Disease-Associated Signatures in a Colorectal Cancer Pilot Study](https://biognosysgroup.com/?resource=2026_asms_poster_thp079)
- [Multi-Platform and Multi-Laboratory Evaluation of a Quantitative Metabolomics Assay Targeting Over 1,200 Metabolites Using AI-Driven Peak Picking](https://biognosysgroup.com/?resource=asms-2026-multi-platform-and-multi-laboratory-evaluation-of-a-quantitative-metabolomics-assay-targeting-over-1200-metabolites-using-ai-driven-peak-picking)
- [High-Performing PepSep Advanced Columns Enable Deep Profiling of P2-Enriched Plasma Samples on the Orbitrap Astral](https://biognosysgroup.com/?resource=2026_asms_poster_mp382)
- [Performance, Carry-Over and Robustness Evaluation of a Newly Available LC-MS/MS Setup for Bottom-Up Proteomics Profiling](https://biognosysgroup.com/?resource=2026_asms_poster_mp377)
- [Standardized Large-Panel Quantitative Metabolomics and Lipidomics Using the biocrates Quant 1000 Kit Validated on the SCIEX Triple Quad 7500 System](https://biognosysgroup.com/?resource=standardized-large-panel-quantitative-metabolomics-and-lipidomics-using-the-biocrates-quant-1000-kit-validated-on-the-sciex-triple-quad-7500-system)
- [Broad Profiling, Quantitative Metabolomics Using the biocrates Quant 1000 Kit Optimized for the Bruker EVOQ DART-TQ+ Mass Spectrometer](https://biognosysgroup.com/?resource=asms-2026-broad-profi-ling-quantitative-metabolomics-using-the-biocrates-quant-1000-kit-optimized-for-the-bruker-evoq-dart-tq-mass-spectrometer)
- [Proteoverse: Digital Proteome for Drug Discovery & Biomarker Research](https://biognosysgroup.com/?resource=cro-data-solutions-digital-proteome)
- [biocrates Data Interpretation and Statistics | Product Number: 496](https://biognosysgroup.com/?resource=biocrates-statistical-package-product-number-496)
- [Brochure | biocrates Quant 1000 Kit](https://biognosysgroup.com/?resource=brochure-biocrates-quant-1000-kit)
- [Data Sheet | NULISAseq CNS Disease Panel 120](https://biognosysgroup.com/?resource=data-sheet-nulisaseq-cns-disease-panel-120)
- [Data Sheet | NULISAseq Mouse Panel 120](https://biognosysgroup.com/?resource=data-sheet-nulisaseq-mouse-panel-120)
- [Data Sheet | NULISAseq Inflammation Panel AQ](https://biognosysgroup.com/?resource=data-sheet-nulisaseq-inflammation-panel-aq)
- [Data Sheet | NULISAseq Inflammation Panel 250](https://biognosysgroup.com/?resource=data-sheet-nulisaseq-inflammation-panel-250)
- [biocrates LxQuant Assay](https://biognosysgroup.com/?resource=lxquant-assay)
- [biocrates Expert Data Consulting | Product Number: 437](https://biognosysgroup.com/?resource=expert-data-consulting)
- [biocrates Data Issue Screening | Product Number: 436](https://biognosysgroup.com/?resource=data-issue-screening)
- [biocrates Study Design Support | Product Number: 435](https://biognosysgroup.com/?resource=study-design-support)
- [Simplify your omics research](https://biognosysgroup.com/?resource=simplify-your-omics-research)
- [Multiomics data analysis](https://biognosysgroup.com/?resource=multiomics-data-analysis)
- [Interpretation and pathway analysis](https://biognosysgroup.com/?resource=interpretation-and-pathway-analysis)
- [biocrates Data Interpretation and Statistics Services](https://biognosysgroup.com/?resource=data-interpretation-and-statistics)
- [biocrates Pathway](https://biognosysgroup.com/?resource=data-and-interpretation-services)
- [biocrates Statistical Package | Product Number: 495](https://biognosysgroup.com/?resource=statistical-package)
- [biocrates Acylcarnitine Assay](https://biognosysgroup.com/?resource=acylcarnitine-assay)
- [biocrates Tryptophan Metabolism Assay](https://biognosysgroup.com/?resource=tryptophan-metabolism-assay)
- [biocrates Short-Chain Fatty Acid Assay](https://biognosysgroup.com/?resource=short-chain-fatty-acid-plus-scfa-assay)
- [biocrates Oxysterol Assay](https://biognosysgroup.com/?resource=oxysterol-assay)
- [biocrates Bile Acids Assay](https://biognosysgroup.com/?resource=absoluteidq-bile-acids-assay)
- [biocrates Stero17 Assay](https://biognosysgroup.com/?resource=absoluteidq-stero17-assay)
- [biocrates p180 Assay](https://biognosysgroup.com/?resource=absoluteidq-p180-assay)
- [biocrates Quant 500 Assay](https://biognosysgroup.com/?resource=mxp-quant-500-assay)
- [biocrates Quant 500 XL Assay](https://biognosysgroup.com/?resource=mxp-quant-500-xl-assay)
- [biocrates MxQuant Assay](https://biognosysgroup.com/?resource=mxquant-assay)
- [biocrates Quant 1000 Assay](https://biognosysgroup.com/?resource=mxp-quant-1000-assay)
- [Poster HUPO 2025 | Immunopeptidomics Profiling of Healthy Tissue Matched to Primary and Metastatic Tumor Samples](https://biognosysgroup.com/?resource=immunopeptidomics-profiling-of-healthy-tissue-matched-to-primary-and-metastatic-tumor-samples)
- [Seminar Recording HUPO 2025 | Plasma Proteomics and Immunopeptidomics: Expert Solutions for Real-World Research Challenges](https://biognosysgroup.com/?resource=plasma-proteomics-and-immunopeptidomics-expert-solutions-for-real-world-research-challenges)
- [Poster SITC 2023 | Development of First-in-Class ERAP2 Inhibitors to Modulate the Cancer Immunopeptidome](https://biognosysgroup.com/?resource=development-of-first-in-class-erap2-inhibitors-to-modulate-the-cancer-immunopeptidome)
- [Poster ASCO 2024 | EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies](https://biognosysgroup.com/?resource=emitt-1-proof-of-mechanism-immunopeptidome-impd-effects-at-target-pk-exposure-in-a-phase-1-study-of-grwd5769-a-first-in-class-inhibitor-of-endoplasmic-reticulum-aminopeptidase-1-erap1-in-patie)
- [AppNote | Precision Meets Depth: Proteomic Solutions for Hard-to-Measure Targets](https://biognosysgroup.com/?resource=precision-meets-depth-proteomic-solutions-for-hard-to-measure-targets)
- [TrueSignature Brochure | Custom Panels for Absolute Protein Quantification](https://biognosysgroup.com/?resource=truesignature-brochure-custom-panels-for-absolute-protein-quantification)
- [AppNote | Absolute Quantification of Fully Customizable Protein Panels Using TrueSignature Targeted Mass Spectrometry](https://biognosysgroup.com/?resource=absolute-quantification-of-fully-customizable-protein-panels-using-truesignature-targeted-mass-spectrometry)
- [One-Pager | Targeted Proteomics for Quantification of Biomarkers and Target Engagement](https://biognosysgroup.com/?resource=targeted-proteomics-for-quantification-of-biomarkers-and-target-engagement)